Romualdo Barroso, MD PhD
@DrRBarroso
Followers
2K
Following
5K
Media
283
Statuses
2K
Medical Oncologist and National Leader of Breast Oncology at Rede Americas #brasilia #Breastcancer #Immunotherapy #clinicalresearch
Brasília, Brasil
Joined December 2015
Proud to present our Trial in Progress at #SABCS. The DESPATIL trial is now enrolling in Brazil 🇧🇷 — a phase II study testing neoadjuvant de-escalation in TNBC based on TILs and imaging response, focusing on efficacy with less toxicity. @DrRBarroso @LauraTestaMD
0
1
5
Well deserved @stolaney1 👏👏👏
The one & only @stolaney1 has been named the 2025 AACR Outstanding Investigator Award for Breast Cancer Research. Congratulations, Dr Tolaney! #SABCS25 @SABCSSanAntonio @DFCI_BreastOnc
1
2
7
Post #ESMO25 Dr. Sara Tolaney (@stolaney1) addresses the remaining questions surrounding the use of #TDXd in the curative-intent setting for #MetastaticBreastCancer. https://t.co/39eQiVCd5p
@VJOncology #MBC #BreastCancer #DESTINYBreast05 #DB05
1
3
16
Honored to share our new collaborative study published in @JCOGO_ASCO We found major disparities in breast cancer care in Brazil - women in the public system wait 93 vs. 41 days to start treatment, and the 60-day Law is not met for over half of them. Proud of this amazing team!
1
1
9
Congrats Beth!
We are excited to share that Elizabeth Mittendorf MD, PhD, MHCM, FASCO, (@EMittendorfMD), has been named: ✨ Chief of Multi-Disciplinary Oncology at @DanaFarber, and ✨Chief of Breast Surgery in the Department of Surgery at @BIDMCSurgery @BIDMChealth. As a nationally and
1
0
2
What happens to an ADC after its infusion? How does it interact with tumor & immune cells, what causes response & resistance? Take a deep dive in the molecular world of ADCs though our last review, led by @AlfredZippelius and published in @NatureRevCancer. https://t.co/oF1cqtOe4p
3
97
346
Check out this npj Breast Cancer review: Unveiling the paradigm shift: Systemic treatment strategies in small, node-negative #BreastCancer 🔓 https://t.co/9RWmS5T3As
@marianascarant1 @renata_bonadio @DrRBarroso
0
11
20
Check out this recent paper on #InflammatoryBreastCancer, it examines the clinicogenomic characterization of #IBC. 👉 https://t.co/reo1YSZPNP
@npriedig @DrBBychkovsky @jenniferbellon2
@TariKingMD @DrEricWiner @lmsholl @stolaney1
@nlinmd @FilipaLynce @DrRBarroso
1
21
38
DESTINY-Breast09: First-line T-DXd + pertuzumab significantly prolongs PFS vs THP in HER2+ mBC: 40.7 vs 26.9 mo (HR 0.56; P<.00001)‼️ New first-line standard? Led by @stolaney1 and discussed by @claudine_isaacs at #ASCO25 #BreastCancer ➡️ https://t.co/erTb74W7Tp
3
25
63
Congrats @EMittendorfMD
We’re proud to announce that Elizabeth Mittendorf, MD, will join BIDMC as Chief of a new Division of Breast Surgery! 👏 A renowned surgeon, she will bring bold leadership to our growing program in collaboration with Dana-Farber. Learn more: https://t.co/W2lb9ZfzZF
0
0
4
We’re proud to announce that Elizabeth Mittendorf, MD, will join BIDMC as Chief of a new Division of Breast Surgery! 👏 A renowned surgeon, she will bring bold leadership to our growing program in collaboration with Dana-Farber. Learn more: https://t.co/W2lb9ZfzZF
5
10
54
Excellent #ASCO25 infographic highlighting the results of the DESTINY-Breast09 study: 👉Participants in the #TDXd + #Pertuzumab arm lived longer without their disease growing, spreading, or getting worse compared with participants in the THP (taxane + trastuzumab + pertuzumab)
2
13
56
Dr Sara Tolaney presenting data of ASCENT-04 with the new 1st line treatment for patients with #TNBC for patients with metastatic PD-L1 positive breast cancer @stolaney1 @DFCI_BreastOnc
1
9
15
Happy to share this review in small, node-negative breast cancer published in npj breast, with some of my greatest mentors! https://t.co/dKiJhMMog9
2
4
9
Thank you @DrRBarroso and all the DFCI team
The #NIMBUS trial results are now published in @NatureComms 👉Nivolumab plus low-dose #ipilimumab in hypermutated HER2-negative #MetastaticBreastCancer. 🔓 https://t.co/iKfaBC5mTO ✍️@jgtzanudo @smreddymd @EmensLeisha @CarolinaAlvesC5 @s_aldubayan @hoyin_chu @nlinmd
@NabihahTayob
0
3
9
The NIMBUS trial of nivo-ipi for TMB-high MBC, led by @DrRBarroso, now published in @NatureComms. Among 30 pts (most with HR+/HER2- dz), ORR was 20%, though the 6 pts with TMB >14 had ORR 60% & PFS 9.5 months. Safety profile favorable (ipi given low dose). https://t.co/e3M1tHrzls
0
18
63
Another one for Dr @stolaney1 She will be presenting the primary results of ASCENT-04 at ASCO 2025 - on May 31st at HALL B1 in the afternoon @DFCI_BreastOnc @DanaFarber @ASCO
#tnbc #immunotherapy #sacituzumabgovitecan #ASCO25
0
20
70
Now is oficial Dr. @stolaney1 will present the primary results of DB09 on June 2nd at Hall D1 at 7:30am #asco25
3
30
132
📢📢📢Jovenes oncologos de latinoamerica 🇦🇷🇺🇾🇨🇱🇧🇷🇨🇴🇵🇪🇪🇨🇵🇾🇧🇴🇲🇽🇨🇷🇵🇦🇬🇹🇳🇮 🇻🇪🇩🇴gran oportunidad para participar del Congreso de @myESMO Breast en Munich 🇩🇪!!! Convocatoria abierta para presentar casos y si es elegido beca de asistencia! Los esperamos con @Rodrosb @StarzerAngelika
0
7
16
Congrat Sara! Well deserved @stolaney1
Congratulations to Dr. Sara Tolaney (@stolaney1) on earning the Fellows of ASCO (FASCO) distinction!
0
0
5